RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)
Adenocarcinoma of Lung|Lung Cancer
DRUG: Oral Restorative Microbiota Therapy (RMT) Capsules|DRUG: Durvalumab 1500 mg IV|DRUG: Cisplatin/pemetrexed or Carboplatin/pemetrexed|OTHER: Placebo
Number of patients experiencing Progression Free Survival (PFS), Incidence of PFS using RECIST 1.1 in each treatment arm to evaluate the efficacy of restorative microbiota therapy, 3 Years|Safety and tolerability of RMT, Safety and tolerability of RMT in combination with durvalumab or durvalumab + chemotherapy as assessed by the incidence of adverse events, 2 Years
Objective Response Rate (ORR) RECIST 1.1, ORR of treatment with RMT in each treatment arm per RECIST 1.1, 2 Years|Duration of Response (DOR), DOR of treatment with RMT in each treatment arm per RECIST 1.1, 2 Years|Overall Survival (OS), Incidence of OS using RECIST 1.1 in each treatment arm, 3 Years|Immune mediated Adverse Events imAE, Rate of immune mediated adverse events (imAE) in each treatment arm, 2 Years|Objective Response Rate (ORR) (iRECIST), ORR using immune response evaluation criteria in solid tumors (iRECIST), 2 Years|Health-related quality of life (QoL), Difference in health-related quality of life (QoL) using European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-30), 2 Years|Health-related quality of life (QoL), Difference in health-related quality of life (QoL) using lung cancer module (LC-13), 2 Years
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)